All In Biotech

Drug Trial Radar · NCT04679935

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Jul 13, 2021

Primary completion

Jan 31, 2024

Study completion Jan 31, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related macular degeneration (AMD) who have previously received anti-VEGF (vascular endothelial growth factor) treatment.

Conditions

  • Age-related Macular Degeneration

Interventions

  • BrolucizumabBiological

    Intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Week 40 to Week 52: LS Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study EyeTime frame: Baseline, Week 40 to Week 52

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Bonn, Germany

  • Novartis Investigative Site

    Düsseldorf, Germany

  • Novartis Investigative Site

    Göttingen, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Homburg, Germany

  • Novartis Investigative Site

    Leipzig, Germany

  • Novartis Investigative Site

    Lübeck, Germany

  • Novartis Investigative Site

    Magdeburg, Germany

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Marburg, Germany

  • Novartis Investigative Site

    Münster, Germany

  • Novartis Investigative Site

    Neubrandenburg, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Regensburg, Bavaria, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site

    Bern, Switzerland

  • Novartis Investigative Site

    Zurich, Switzerland

  • Novartis Investigative Site

    Lausanne, CHE, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.